Introduction to Bayesian methods III: use and interpretation of Bayesian tools in design and analysis
暂无分享,去创建一个
[1] D. Berry,et al. Bayesian Survival Analysis With Nonproportional Hazards , 2004 .
[2] D. Berry,et al. Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] Terry L. Smith,et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] Peter E. Rossi,et al. Case Studies in Bayesian Statistics , 1998 .
[5] D. Berry. Bayesian Statistics and the Efficiency and Ethics of Clinical Trials , 2004 .
[6] Peter F Thall,et al. Seamlessly Expanding a Randomized Phase II Trial to Phase III , 2002, Biometrics.
[7] J. Couzin. The New Math of Clinical Trials , 2004, Science.
[8] Michael D. Smith,et al. Adaptive Bayesian Designs for Dose-Ranging Drug Trials , 2002 .
[9] Scott M Berry,et al. Accounting for Multiplicities in Assessing Drug Safety: A Three‐Level Hierarchical Mixture Model , 2004, Biometrics.